Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 6/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27199811 | 0.94 | TERT (0.50) | CSNK2A1CSNK2A2CSNK2BTERTNQO1 | |
| SCHEMBL29615014 | 0.80 | TERT (0.63) | CSNK2A1TERTNQO1GSK3AGSK3B | |
| SCHEMBL3510262 | 0.80 | TERT (0.63) | CSNK2A1TERTNQO1GSK3AGSK3B | |
| SCHEMBL27199808 | 0.79 | PGK1 (0.40) | TERTNQO1GSK3AGSK3BEGFR | |
| SCHEMBL31485507 | 0.79 | CSNK2A1 (0.46) | CSNK2A1CSNK2A2CSNK2BTERTTOP2A | |
| SCHEMBL31454005 | 0.78 | CSNK2A1 (0.49) | CSNK2A1CSNK2A2CSNK2BTERTTOP2A | |
| SCHEMBL27092618 | 0.78 | CSNK2A1 (0.49) | CSNK2A1CSNK2A2CSNK2BTERTTOP2A | |
| SCHEMBL27199817 | 0.78 | EGFR (0.46) | NQO1GSK3AGSK3BPAX8EGFR | |
| SCHEMBL27199813 | 0.76 | KDM1A (0.45) | EGFR | |
| SCHEMBL27075670 | 0.74 | TERT (0.47) | CSNK2A1CSNK2A2CSNK2BTERTTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964976-B1 | Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors | King Faisal University (SA) | 2024-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964976-B1 | Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors | CKS2, CDK2, CDK1 | CSNK2A1 9/4885CSNK2A2 13/4885CSNK2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.